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Abstract
Background: Deposition of amyloid-β (Aβ) in vessel walls of the brain as cerebral amyloid
angiopathy (CAA) could be a major factor in the pathogenesis of dementia. Here we investigate the
relationship between dementia and the prevalence of CAA in older populations. We searched the
literature for prospective population-based epidemiological clinicopathological studies, free of the
biases of other sampling techniques, which were used as a comparison.
Methods: To identify population-based studies assessing CAA and dementia, a previous systematic
review of population-based clinicopathological studies of ageing and dementia was employed. To
identify selected-sample studies, PsychInfo (1806–April Week 3 2008), OVID MEDLINE (1950–
April Week 2 2008) and Pubmed (searched 21 April 2008) databases were searched using the term
"amyloid angiopathy". These databases were also employed to search for any population-based
studies not included in the previous systematic review. Studies were included if they reported the
prevalence of CAA relative to a dementia classification (clinical or neuropathological).
Results: Four population-based studies were identified. They showed that on average 55–59% of
those with dementia displayed CAA (of any severity) compared to 28–38% of the non-demented.
37–43% of the demented displayed severe CAA in contrast to 7–24% of the non-demented. There
was no overlap in the range of these averages and they were less variable and lower than those
reported in 38 selected sample studies (demented v non-demented: 32–100 v 0–77% regardless of
severity; 0–50 v 0–11% for severe only).
Conclusion: CAA prevalence in populations is consistently higher in the demented as compared
to the non-demented. This supports a significant role for CAA in the pathogenesis of dementia.
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Alzheimer's disease (AD) is the most common type of
dementia and is characterised pathologically by the
intraneuronal accumulation of neurofibrillary tangles
(NFT) containing tau and ubiquitin, and by the extracel-
lular accumulation of amyloid-β (Aβ) in brain tissue and
in artery walls as cerebral amyloid angiopathy (CAA).
Many studies have correlated the severity of dementia in
AD with the number and distribution of NFTs, the
number of plaques of insoluble Aβ, and the levels of sol-
uble Aβ in the brain [as reviewed by [1]]. Relatively few
studies, however, have investigated the relationship
between dementia and the key pathological change of
CAA.
CAA is the deposition of the amyloid peptides, of which
Aβ is the most common, in the media and adventitia of
small to medium-sized cerebral and leptomeningeal arter-
ies, and less commonly in the walls of capillaries and
veins [2-5]. The occipital lobe is most often involved, the
frontal, parietal and temporal lobes less so and the cere-
bellum least; CAA is rare in the thalamus, basal ganglia
and white matter [6,7]. Scholz [8] first emphasized the
presence of CAA, suggesting that the pathological feature
was associated with 'senility'. However, CAA was only
reported to be a risk factor for dementia in the 1980s [9-
11]. There has since then been increasing evidence to sup-
port this proposal [12,13] and CAA is now thought to play
a significant role in the production of dementia [14-16].
Hereditary and sporadic types of CAA have been defined
[17,18] however this review focuses on the common spo-
radic CAA found in the old.
The cause and effects of CAA have generated much debate
especially in relation to dementia [19,20]. CAA represents
the failure of elimination of Aβ along the perivascular
pathways that serve as the lymphatic drainage channels
for the brain [20]. Soluble tracers injected into the mouse
striatum drain out of the brain along basement mem-
branes of capillary and artery walls [21]. In CAA, Aβ is
deposited in the very same perivascular drainage path-
ways outlined, in capillary and artery walls, in the injec-
tion studies in mice. This suggests that there is a failure of
elimination of Aβ along ageing cerebral and leptomenin-
geal arteries [20,22,23]. Stiffening of artery walls with age
and cerebrovascular disease may be a key element in
reducing the elimination of Aβ from the brain in the eld-
erly and in AD [20,24,25]. Transgenic mice that overpro-
duce Aβ only in the brain develop CAA [19] which further
supports the hypothesis that, in CAA, Aβ is entrapped in
the perivascular pathways by which fluid and solutes
drain from the brain [20,22].
Two major consequences arise from CAA. First: arteries
weakened by deposits of Aβ in their walls tend to rupture
and result in CAA-related intracerebral haemorrhage
[26,27]. Second: blockage of perivascular drainage path-
ways by Aβ may be associated with accumulation of Aβ in
the brain. Ultimately it is increased levels of soluble Aβ
that correlates with cognitive decline in patients with AD
[28,29]. It is possible that drainage of other soluble
metabolites from the brain may also be impeded in CAA.
This would result in a loss of homeostasis in the neuronal
extracellular environment that could contribute to cogni-
tive decline in AD [20].
CAA has been related to other neuropathological markers
of dementia including neuritic plaques and NFTs [30-32].
The amount of phospho-tau in neurites was found to be
greater in grey matter surrounding cerebral vessels affected
by CAA than in grey matter away from affected vessels
[33]. The relationship between CAA and other neu-
ropathologies is not simple however, and there is great
heterogeneity in CAA severity in brains with AD-type
pathology [34]. CAA has been reported to affect cogni-
tion/dementia status independently of other neuropatho-
logical markers of dementia [3,7,12,35,36]. However, in
one study CAA was found to be associated with dementia
only in those who lacked any AD-type pathology [37].
Assessing the possible impact of CAA or any neuropatho-
logical marker of dementia is best done using a sample
that closely reflects the population at risk [38]. The vast
majority of studies assessing the relationship between
CAA and dementia have assessed selected samples (e.g.,
necropsy and hospital patients) which do not reflect the
population at risk, in terms of either clinical or age pro-
files. Many of these studies have had access to limited clin-
ical information, which further limits the interpretation of
results. Thus, although CAA has been reported to play a
significant role in the causation of dementia, it is
unknown whether this is partly an artefact of using highly
selected samples and/or the predominant use of neu-
ropathological dementia classifications such as AD
(which most likely relates to CAA closer than clinical diag-
noses). The role of CAA in dementia at a population level
is uncertain.
Our aim in this study was to investigate the importance of
CAA in relation to dementia in a population-based con-
text. We have addressed this by systematically reviewing
previous studies that have assessed the relationship
between CAA and dementia in prospectively sampled
population-based cohorts of elderly people. For compari-
son, we have systematically reviewed studies of CAA on
selected samples.
Methods
Identifying population-based studies for review
A systematic review of population-based neuropathologi-
cal studies of ageing and dementia in older people was
published in 2006 [39]. Six studies were identified asPage 2 of 8
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(Japan), Vantaa 85+ (Finland), the Cambridge City over
75 Cohort (CC75C; England), the Honolulu-Asia Aging
Study (HAAS; USA), the Cache Country Study (USA) and
the MRC Cognitive Function and Ageing Study (CFAS;
England and Wales). To identify articles for the current
review, PsychInfo (1806–April Week 3 2008), OVID
MEDLINE (1950–April Week 2 2008) and Pubmed
(searched 21 April 2008) databases were used to search
for papers employing any of these six study populations to
assess CAA. Study titles were searched for as keywords,
along with 'amyloid angiopathy'. When no study could be
found using the key term 'amyloid angiopathy', it was
replaced by 'neuropathology' and the relevant articles
were read and searched to determine if CAA was assessed.
To ensure that no further prospective population-based
clinicopathological studies had been published since Zac-
cai et al. [39], a search was conducted using the same data-
bases detailed above using the terms 'population' and
'amyloid angiopathy' or 'pathology'. No new studies were
identified.
Identifying selected-sample studies for review
To compare CAA prevalence rates in population-based
studies with those in studies of selected samples, we con-
ducted a systematic review of studies in which CAA prev-
alence was determined relative to dementia status.
To identify studies using selected samples the PsychInfo
(1806–April Week 3 2008), OVID MEDLINE (1950–April
Week 2 2008) and Pubmed (searched 21 April 2008)
databases were searched. One thousand three-hundred
and seventy-three studies were identified using the search
term 'amyloid angiopathy'. Titles and abstracts from these
studies were read and studies were excluded if they did not
assess human cases, the prevalence of CAA in the
demented and/or non-demented specifically related to
hereditary/familial CAA, reported a sample with a n less
than 10, reported CAA prevalence relative to a condition
other than dementia or only a feature of dementia (e.g.,
Parkinson's disease or APOE genotype), selected cases
based on the presence of CAA, if they clearly reported the
same cases as a previously selected study [e.g., [30,40,41]],
if analyses were not neuropathological (e.g., MRI), or had
been included as one of the population-based studies
described above. The search was restricted to the English
language. When a decision could not be made as to
whether the article should be excluded, full articles were
read. When articles were read, any cited articles that were
not identified during the search were included.
Results
Summary of findings from population-based studies
Five of the six population-based studies reported CAA
prevalence rates [13,14,35,42,43], of which four calcu-
lated these rates relative to dementia status (demented
and/or non-demented) prior to death [all but [43]]. The
findings from the four studies identified are reviewed
below and summarised in Additional file 1. None of the
studies assessed sex differences and only one study pro-
vided prevalence relative to age-groups [14] and thus
prevalence relative to age and sex factors are not shown.
Cambridge City over 75 Cohort (CC75C)
Xuereb et al. [42] reported on CAA prevalence in the
CC75C. The study comprised 99 individuals (68%
women) over 80 years of age. CAA was assessed in menin-
geal and parenchymal areas of the occipital, frontal, tem-
poral and parietal cortices as well as in the hippocampus.
All CAA was recorded, regardless of severity. The authors
reported that regardless of distribution, brains from par-
ticipants with clinical dementia had a significantly higher
prevalence of CAA (55%) than brains from participants
who were not demented (26%).
MRC Cognitive Function and Ageing Study (MRC-CFAS)
MRC-CFAS [14] assessed the association between severe
CAA and clinical dementia in 209 (57% female) individ-
uals from England with a mean age of 86 years. Parenchy-
mal and meningeal CAA was scored in the entorhinal,
frontal, temporal, parietal and occipital cortices as well as
the hippocampus. Severe CAA was present in 37% of the
clinically demented and 7% of the non-demented, and
was significantly associated with dementia (odds ratio/
OR 9.3, 95%, confidence interval/CI 2.7–41.0) independ-
ent of other dementia-related neuropathologies.
Honolulu-Asia Aging Study (HAAS)
Pfeifer et al. [13] assessed CAA (controlling for other
dementia-related neuropathologies) and clinical demen-
tia in Japanese-American men in the HAAS. CAA was
assessed in frontal, temporal, parietal and occipital corti-
ces in 211 cases. Those with CAA were more likely to be
older (86 versus 84 years of age) and carry at least one
APOE ε4 allele (23% versus 6%) than were those without
CAA. The prevalence of CAA regardless of severity did not
vary significantly between the demented and non-
demented, with rates of 55% and 38% respectively (signif-
icance value not provided). Accordingly, the authors con-
cluded that CAA regardless of severity did not confer a
significant risk for dementia. There was however a signifi-
cant difference in the prevalence of severe CAA, with the
demented having a higher prevalence (43%) than the
non-demented (24%).
Vantaa 85+ study
Tanskanen et al. [35] assessed CAA in 74 (82% women)
Finnish individuals over the age of 95 who were part of
the Vantaa 85+ study. CAA severity was assessed in frontal,
parietal, temporal, cingulate and cerebellar cortices, andPage 3 of 8
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[13], those with CAA were more likely to have at least one
APOE ε4 allele – 45% as compared to 8%. Of the clini-
cally demented, 59% had CAA as compared to 28% of the
non-demented. It was reported that moderate or severe
CAA conferred a risk for dementia (OR not reported).
From the summaries and Additional file 1  it is evident
that in population-based samples, the prevalence of CAA
is higher in the demented than the non-demented. On
average, 55–59% of those with clinical dementia had CAA
(regardless of severity) compared to 28–38% of the non-
demented. For severe CAA, prevalence appeared to
decrease relatively equally across demented and non-
demented groups, 37–43% of the clinically demented dis-
playing severe CAA as compared to 7–24% of the non-
demented. Only one study reported the prevalence of
CAA to be non-significantly higher in demented than
non-demented individuals however, this was for CAA
regardless of severity. When only severe CAA was assessed,
those with dementia had a higher prevalence than did the
non-demented [13]. This suggests that in the population,
severe CAA may be a better discriminator of clinical
dementia than CAA regardless of severity.
Summary of selected-sample studies
Thirty-eight studies were identified for review and are
summarised in Additional file 2. It can be seen in Addi-
tional file 2 that the prevalence of CAA, regardless of
severity, is higher in the demented (32–100% regardless
of subtype or 47–100% for AD-only) than the non-
demented (0–77%) in selected samples. The studies that
assessed severe CAA reported prevalence rates of 0–50%
in the demented (6–50% for AD-only) and 0–11% in the
non-demented. Only five of the thirty-eight selected stud-
ies tested for an association between CAA and dementia
[34,37,40,44,45]. All of those that did reported that cases
with dementia had a significantly higher prevalence than
those without, or that CAA prevalence correlated signifi-
cantly with dementia. The only exception was the study by
Jellinger and Attems [40] in which this was true for capil-
lary CAA but not other forms of CAA.
Discussion
How do CAA prevalences differ between population-based 
and selected-sample studies?
There was greater variability in CAA prevalence rates in
selected-sample studies than population-based studies.
This may be due to differential bias between selected sam-
ples and the paucity of clinical information prior to death
in most studies.
Estimates of CAA prevalence in the population studies
were lower than in those from selected samples. This may
be due to diagnostic differences (primarily neuropatho-
logical methods in studies of selected samples as com-
pared to clinical methods in population-based studies)
and younger populations being assessed, perhaps includ-
ing some cases of hereditary rather sporadic CAA. Only
eight studies of selected samples employed a clinical diag-
nosis of dementia rather than a neuropathological confir-
mation of AD or VaD. This is an important difference
from population-based studies, all of which employed a
clinical diagnosis, as neuropathological and clinical AD
classification methods correspond imprecisely [46,47].
The mean age of the cohorts in selected-sample studies
was between 69–91, with participants in their 40s and 50s
commonly included [e.g., [44,48-50]]. These studies on
selected samples therefore included much younger cases
than population-based studies. Given that population-
based studies most closely reflect the population at risk of
disease, these findings highlight their important contribu-
tion to the understanding of pathological correlates of
clinically determined dementia relevant to populations
and patients. Evidence relating to the pathology of
dementia needs to be obtained from both population-
based as well as from selected samples.
Both the population-based studies and those on selected
samples employed various stains to assess CAA, including
Congo red, thioflavin-S, anti-Aβ immunohistochemistry
and Weigert's haematoxylin. Some studies used multiple
stains – either different stains for different cases [e.g., [51]]
or anti-Aβ immunostaining to validate Congo red-posi-
tive cases [e.g., [34]]. To the authors' knowledge, no study
has directly compared the sensitivity and specificity of
these staining methods in relation to the measurement of
CAA. Haglund and Englund [49] assessed a small sample
(n = 10) with both Congo red and anti-Aβ immunohisto-
chemistry. They reported that for 8 of the 10 cases, CAA
severity appeared similar with both methods (Aβ immu-
nohistochemistry perhaps giving slightly higher severity
grades), while the other 2 cases showed little Congo red
positivity but strong labelling of vascular Aβ.
It is not only the staining method that may produce vari-
ability between studies, the pre-treatment methods and
sampling strategies also contribute [52,53]. The selection
of parenchymal and/or leptomeningeal samples is also
important, as CAA severity is usually higher in the later
[54]. The choice of cortical region(s) and the grading sys-
tem employed in the scoring of CAA in terms of its scale
(e.g., 0–3 or 0–4) and definition of severity, would have
also contributed to inter-study variability.
CAA at the population level including risk factors
At the population level, it appears as though CAA preva-
lence rates are consistently higher in the demented than
the non-demented, suggesting that CAA is an importantPage 4 of 8
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particularly severe CAA. This finding is pertinent in light
of recent reports of overlap in the prevalence rates
between demented and non-demented cohorts of other
dementia-related abnormalities such as plaques and tan-
gles [14,47].
Determination of the presence and severity of CAA may
aid in neuropathological assessment that more closely
resembles the clinical assessment of dementia. The MRC-
CFAS study reported the OR for risk of a clinical dementia
diagnosis to be higher for severe CAA (OR = 9.3, 95%CI
2.7–41.0) than either neocortical neuritic plaques (OR =
5.0, 95%CI 1.2–29.8) or neocortical tangles (OR = 4.6,
95%CI 1.5–15.8) [14]. Future work should elucidate
whether the inclusion of CAA in the neuropathological
assessments of dementias such as AD improves the specif-
icity and sensitivity of classification relative to clinical
dementia during life. Further, given that CAA is a poten-
tial discriminator of dementia from normal ageing, imag-
ing methods that detect CAA in living individuals may aid
in the differential diagnosis of clinical dementia syn-
dromes [5,12,55]. CAA is a potential predictor of the
development of dementia during life, for which treatment
and management strategies might be developed. The pres-
ence of CAA in the living non-demented may also indicate
a specific syndrome such as Vascular Cognitive Impair-
ment No-Dementia (VCI-ND) [56] – this also needs to be
investigated in the future.
Some studies [6,34,43,57-60] but not all [14,48,61] have
found that increasing age in the elderly is a risk factor for
CAA. In a community sample of 100 individuals 50–91
years, Mastaglia et al. [62] found CAA prevalence to
increase with age to a maximum in those over 90. As yet
there is no evidence that the prevalence of CAA varies with
sex [7,43]. Cerebrovascular disease (e.g., atherosclerosis)
is another possible risk factor for CAA. It has been sug-
gested to affect the efficiency of Aβ removal by perivascu-
lar drainage, leading to CAA [63]. However, hypertension,
diabetes mellitus and hyperlipidemia do not appear to be
risk factors for CAA [60].
The ε4 allele of the APOE gene has been reported to be a
risk factor for CAA as it is for AD [64-68] and this was seen
in two of the population-based studies reviewed here
[13,35]. It has been suggested that the association
between the APOE ε4 allele and CAA is due to the ε4 allele
being related to vascular rather than parenchymal accu-
mulation of Aβ [64]. The APOE ε4/ε4 genotype has been
associated with CAA-related inflammation [69], while the
ε2 allele has been reported to be a risk factor for CAA-
related haemorrhage in both those with and those with-
out AD [65,70].
How clinical studies can inform these findings
Studies of clinic and/or necropsy cohorts are valuable for
determining the implications of CAA at a population
level. For instance, these studies have found that many
neurological events induced by CAA can themselves com-
promise neurological integrity and cognitive function. For
example, CAA increases vessel wall fragility and increases
the risk of cortical and subcortical intracerebral haemor-
rhage [5,71], carrying a high risk of poor neurological and
cognitive outcome [72]. CAA may impair blood flow,
leading to ischemic damage to the cerebral cortex and
white matter, which is also associated with neurological
and cognitive impairment [73-75]. CAA is associated with
failure of drainage of interstitial fluid from cerebral white
matter in AD and the pathogenesis of leukoaraiosis [76].
Further, the Aβ peptide that accumulates in CAA can pro-
voke inflammation/vasculitis in a small subset of individ-
uals [69,77] with both microglia and T-cells involved
[78]. CAA-related inflammation has also been proposed
to be related to severe cognitive decline due to circulatory
dysfunction [69,78]. Thus, patients who develop haemor-
rhage, ischaemia, white matter damage or inflammation
as complications of CAA are at risk of further cognitive
impairment.
The type of vessel involved and distribution of CAA may
differentially affect cognition. It was reported that capil-
lary CAA is more closely associated with impaired cogni-
tion than is CAA of larger blood vessels [30,79]. Further,
although CAA is most prevalent in the posterior regions of
the cerebral hemispheres, the association between CAA
and clinical dementia has been reported to be strongest
for frontal CAA [37].
Possible limitations and future directions
The four population-based studies reviewed here
employed relatively crude measures of CAA. There were
varying attempts to take into account the interactions with
a wide range of other dementia-related pathologies and
the severity of CAA. No study took into account the distri-
bution of CAA, the presence of inflammation and the type
of vessel affected. All these factors have been reported to
influence the association with cognition [e.g.,
[30,37,79,80]].
Population-based studies, as with studies on selected sam-
ples, face some important stumbling blocks in the investi-
gation of CAA. The distribution of CAA is variable [4] and
its detection critically dependent of the extent and distri-
bution of histological sampling. There is likely to be an
under-diagnosis of CAA even in severe cases [18]. There is
currently no consensus as to how to sample for or detect
CAA or grade its severity. Full evaluation of CAA is most
satisfactorily assessed by isolating cerebral and leptome-Page 5 of 8
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with Thioflavin [22,76]. A standard consensus method for
detecting and classifying CAA would greatly facilitate
future population-based multi-centre studies of CAA and
such plans are underway.
Conclusion
CAA prevalence rates are higher in demented than non-
demented old people in prospective population-based
studies. This suggests that CAA is a more significant
dementia-related abnormality than previously recognised
and underscores the need to understand the aetiology and
pathogenesis of CAA and its contribution to dementia in
the population.
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